The ACER1 Knockout T-47D Polyclonal Cells product from Ascent Research represents a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the ACER1 gene in the T-47D human breast cancer cell line. This knockout model provides a valuable in vitro system for investigating the role of ACER1 in sphingolipid metabolism and associated signaling networks without altering the genetic background of the well-characterized T-47D cell line. The polyclonal nature ensures heterogeneous editing across the cell population, enabling robust functional studies of gene loss.
The T-47D host cell line is an estrogen receptor-positive (ER+) luminal A breast cancer model derived from the pleural effusion of a 54-year-old female with infiltrating ductal carcinoma. Widely used in breast cancer research, T-47D cells exhibit hormone-dependent growth and retain features of luminal epithelial differentiation, making them particularly suitable for studying endocrine signaling and apoptosis. Their stable karyotype and well-documented transcriptomic profile facilitate integrative analyses in knockout studies.
ACER1 encodes an alkaline ceramidase that catalyzes the hydrolysis of ceramides into sphingosine and free fatty acids, thereby depleting pro-apoptotic ceramide species and producing sphingosine that can be phosphorylated by sphingosine kinases (SPHK1, SPHK2) to generate sphingosine-1-phosphate (S1P), a potent survival factor. This enzymatic function positions ACER1 as a critical regulator of the ceramide/S1P rheostat, influencing apoptosis, differentiation, and tumor cell survival. Upstream of ACER1, the p63 transcription factor and Notch signaling have been implicated in its regulation, while downstream, S1P activates its cognate receptors (S1PR1-5) to promote anti-apoptotic pathways including Bcl-2 expression. ACER1 functionally competes with ceramide synthases (e.g., CERS2, CERS5) for ceramide substrates and is metabolically coupled to sphingosine kinases, linking it directly to the sphingomyelinase (SMPD1)-initiated ceramide generation pathway.
In the context of T-47D breast cancer cells, ACER1 knockout is particularly relevant for dissecting how aberrant ceramide metabolism contributes to apoptosis evasion and therapeutic resistance in ER+ luminal A tumors. By eliminating ACER1 activity, these polyclonal knockout cells allow researchers to examine the accumulation of ceramides and their impact on cell viability, endoplasmic reticulum stress responses, and sensitivity to chemotherapeutic agents. The model provides a platform to assess the interplay between estrogen signaling and sphingolipid metabolism, offering insights into potential therapeutic vulnerabilities.
These ACER1 knockout T-47D cells are ideally suited for a range of advanced applications, including quantitative ceramide profiling by LC-MS, validation of target engagement via western blotting and RT-qPCR, functional apoptosis assays such as annexin V staining, and genome-wide transcriptomic analysis using RNA-seq. Researchers can employ this tool to investigate the ceramide/S1P balance in breast cancer, perform drug sensitivity testing, and study sphingolipid metabolism in a well-defined genetic context. For further information and technical inquiries, please contact Ascent Research.
